JP5335677B2 - 環状化合物を含む製剤 - Google Patents

環状化合物を含む製剤 Download PDF

Info

Publication number
JP5335677B2
JP5335677B2 JP2009529613A JP2009529613A JP5335677B2 JP 5335677 B2 JP5335677 B2 JP 5335677B2 JP 2009529613 A JP2009529613 A JP 2009529613A JP 2009529613 A JP2009529613 A JP 2009529613A JP 5335677 B2 JP5335677 B2 JP 5335677B2
Authority
JP
Japan
Prior art keywords
cyclic
protonated
acid
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009529613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010504934A (ja
JP2010504934A5 (enExample
Inventor
ボッティ，パオロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2010504934A publication Critical patent/JP2010504934A/ja
Publication of JP2010504934A5 publication Critical patent/JP2010504934A5/ja
Application granted granted Critical
Publication of JP5335677B2 publication Critical patent/JP5335677B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D323/00—Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009529613A 2006-09-27 2007-09-27 環状化合物を含む製剤 Expired - Fee Related JP5335677B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06020286A EP1905454A1 (en) 2006-09-27 2006-09-27 Formulations comprising cyclic compounds
EP06020286.8 2006-09-27
PCT/EP2007/008442 WO2008037484A2 (en) 2006-09-27 2007-09-27 Formulations comprising cyclic compounds

Publications (3)

Publication Number Publication Date
JP2010504934A JP2010504934A (ja) 2010-02-18
JP2010504934A5 JP2010504934A5 (enExample) 2010-12-09
JP5335677B2 true JP5335677B2 (ja) 2013-11-06

Family

ID=37728182

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009529613A Expired - Fee Related JP5335677B2 (ja) 2006-09-27 2007-09-27 環状化合物を含む製剤

Country Status (10)

Country Link
US (1) US8513188B2 (enExample)
EP (2) EP1905454A1 (enExample)
JP (1) JP5335677B2 (enExample)
CN (2) CN101557829A (enExample)
AU (1) AU2007302270B2 (enExample)
BR (1) BRPI0714761B8 (enExample)
CA (1) CA2664568C (enExample)
ES (1) ES2691736T3 (enExample)
IL (1) IL197760A (enExample)
WO (1) WO2008037484A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010323117B2 (en) 2009-11-25 2015-09-03 Capsugel Belgium Nv Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
EP2332929A1 (en) * 2009-11-25 2011-06-15 ArisGen SA Orthoester derivatives of crown ethers as carriers for pharmaceutical and diagnostic compositions
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
CN102863358B (zh) * 2012-09-20 2014-02-12 华中农业大学 具有除草活性的化合物及其制备方法
EP3000811B1 (en) * 2014-09-24 2017-11-08 Friedrich-Alexander-Universität Erlangen-Nürnberg Crown Ether Complexes and Methods for Poducing the Same
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN108658264B (zh) * 2018-04-17 2021-05-25 唐山师范学院 多支化聚环氧琥珀酸衍生物阻垢缓蚀剂的制备及其应用方法
CN113527672B (zh) * 2020-03-30 2022-09-20 复旦大学 一种胍基衍生物及其基因递释系统
CN116178887B (zh) * 2023-02-16 2024-10-29 东华大学 一种可降解快递袋材料及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2923787A1 (de) * 1979-06-12 1980-12-18 Max Planck Gesellschaft Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
US4474753A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
AU6738487A (en) * 1985-12-04 1987-06-30 Hsieh, D. Transdermal delivery of drugs
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
EP2280004B1 (en) * 1999-06-29 2016-04-20 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
CN1379771A (zh) * 1999-09-20 2002-11-13 天藤制药株式会社 环状乳酸齐聚物的制备方法
US7169814B2 (en) * 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
JP2006232909A (ja) * 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸

Also Published As

Publication number Publication date
AU2007302270A1 (en) 2008-04-03
US20100137188A1 (en) 2010-06-03
CN101541346B (zh) 2014-07-02
EP2068934A2 (en) 2009-06-17
JP2010504934A (ja) 2010-02-18
CA2664568C (en) 2015-11-24
BRPI0714761B1 (pt) 2021-03-23
AU2007302270B2 (en) 2014-05-29
IL197760A (en) 2016-10-31
BRPI0714761A2 (pt) 2013-07-02
CN101557829A (zh) 2009-10-14
IL197760A0 (en) 2009-12-24
ES2691736T3 (es) 2018-11-28
WO2008037484A2 (en) 2008-04-03
CA2664568A1 (en) 2008-04-03
BRPI0714761B8 (pt) 2021-05-25
US8513188B2 (en) 2013-08-20
EP2068934B8 (en) 2018-09-05
WO2008037484A3 (en) 2008-12-18
CN101541346A (zh) 2009-09-23
EP2068934B1 (en) 2018-07-18
EP1905454A1 (en) 2008-04-02

Similar Documents

Publication Publication Date Title
JP5335677B2 (ja) 環状化合物を含む製剤
Kong et al. Long acting hyaluronate–exendin 4 conjugate for the treatment of type 2 diabetes
EA011351B1 (ru) Полимерные реагенты, способы их получения, а также содержащие их конъюгаты и фармацевтические препараты
IL220003A (en) A drug release device
JP2019196399A (ja) 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
KR101201473B1 (ko) 자기 조립형 약물 및 세포 전달체의 제조 방법 및 이에 의해 제조된 자기 조립형 약물 및 세포 전달체
Bauer et al. Tuning the cross-linking density and cross-linker in core cross-linked polymeric micelles and its effects on the particle stability in human blood plasma and mice
JP5848708B2 (ja) 医薬および診断組成物用の担体としてのクラウンエーテルのオルトエステル誘導体
JP6050332B2 (ja) 薬物の粘膜投与
CA3222510A1 (en) Ghr-binding pending peptide and composition comprising same
CN117126397A (zh) 蛋白结合型精准聚乙二醇的合成方法及应用
CN100404585C (zh) 一种聚氧乙烯类嵌段聚合物配体及其合成方法
WO2019212377A1 (ru) Фармацевтическая композиция на основе полимиксина для лечения инфекционных заболеваний
HK1246333A1 (zh) 制备具有优异的肽和蛋白结合性质的接枝共聚物赋形剂的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130618

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130718

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130724

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130731

R150 Certificate of patent or registration of utility model

Ref document number: 5335677

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees